Placebp — Competitive Intelligence Brief

Placebp (placebp) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Placebo. Area: Neuroscience.

marketed Placebo None Neuroscience

Target snapshot

Placebp (placebp) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebp TARGET	placebp	Pfizer	marketed	Placebo	None	Not applicable
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Dicuman	dicoumarol	AbbVie	marketed	dicoumarol	NAD(P)H dehydrogenase [quinone] 1	1944-01-01
Xibrom, and Optive	Xibrom, and Optive	Bp Consulting, Inc	marketed	Topical NSAID (Xibrom); Artificial tear/lubricant (Optive)	COX-1/COX-2 (Xibrom); None—lubricant formulation (Optive)
FLUNIXIN	FLUNIXIN		marketed		Dihydroorotate dehydrogenase (quinone), mitochondrial
Eplerenone vs Amlodipine	Eplerenone vs Amlodipine	Brigham and Women's Hospital	marketed	Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine)	Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)
Flecainide or Sotalol or Propafenone	Flecainide or Sotalol or Propafenone	Medtronic Cardiac Rhythm and Heart Failure	phase 3	Antiarrhythmic agents (Class I and Class III)	Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Placebo class)

1. Pfizer · 1 drug in this class
2. Tehran University of Medical Sciences · 1 drug in this class